- Home
- AGMB vs ORIC Comparison
AGMB vs ORIC Comparison
Compare AGMB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMB | ORIC |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.7M | 861.3M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AGMB | ORIC |
|---|---|---|
| Price | $13.29 | $13.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $32.00 | $19.73 |
| AVG Volume (30 Days) | 89.6K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $7.23 |
| 52 Week High | $17.82 | $14.93 |
Technical Indicators
Market Signals| Indicator | AGMB | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 63.52 |
| Support Level | $9.54 | $10.45 |
| Resistance Level | $14.19 | $14.14 |
| Average True Range (ATR) | 1.05 | 0.88 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 29.81 | 83.69 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.